GSK PLC Sponsored ADR $GSK Shares Sold by Focus Partners Wealth

Focus Partners Wealth decreased its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 3.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,666 shares of the pharmaceutical company’s stock after selling 1,265 shares during the quarter. Focus Partners Wealth’s holdings in GSK were worth $1,537,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. HHM Wealth Advisors LLC raised its holdings in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of GSK during the first quarter valued at approximately $31,000. Richardson Financial Services Inc. raised its holdings in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock valued at $33,000 after acquiring an additional 472 shares during the last quarter. Olde Wealth Management LLC acquired a new position in shares of GSK during the first quarter valued at approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in shares of GSK by 525.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company’s stock valued at $39,000 after acquiring an additional 852 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on GSK shares. Berenberg Bank reissued a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Six equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $37.38.

GSK Trading Down 0.6%

Shares of GSK stock opened at $40.04 on Wednesday. The firm has a market capitalization of $81.55 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 2.01 and a beta of 0.53. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $43.14. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The stock has a 50 day moving average of $38.81 and a 200 day moving average of $38.50.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK’s dividend payout ratio is presently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.